Receptor News and Research

RSS

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).

5 Oct 2010

Researchers reveal ways to halt Rett Syndrome

In a study published today in the Journal, Proceedings of the National Academy of Sciences, an international team of researchers based in the U.S. and UK revealed that they were able to halt the potentially lethal, breath holding episodes associated with the neurological disease Rett syndrome.

5 Oct 2010

Study finds BRACAnalysis vital for triple negative breast cancer patients

Myriad Genetics, Inc. announced today that results from a preliminary study indicate that BRCA germline mutations occur at a high frequency in women with triple negative breast cancer, sufficiently high enough to justify screening of all women with TNBC.

5 Oct 2010

Second pathway to brain’s memory function uncovered

Australian and US scientists have successfully identified a new mechanism by which the brain learns and stores memories. This could spell hope for brain injuries and diseases like Alzheimer’s disease.

4 Oct 2010

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

4 Oct 2010

Study demonstrates potential of nontoxic envelope proteins as an alternative to pseudotype lentiviral vectors

Therapeutic lentiviral vectors are emerging as vital tools for molecular medicine as evidenced by the growing number of clinical trials using these vector systems. From a basic research standpoint, lentiviral vectors are very intriguing substrates. On the one hand, the HIV-1 genome offers expanded cloning capacity and the capability to transduce nondividing cells such as hematopoietic stem cells (HSCs) and neurons.

4 Oct 2010

NIH awards Scripps Research grants to study the mechanisms of protein complex

For Immediate Release -Scripps Research Institute scientists have been awarded approximately $65 million in four five-year grants as part of the National Institutes of Health's (NIH) latest round of structural biology funding. The projects will focus on determining the shapes and functions of proteins and protein complexes that are important in biology and medicine.

4 Oct 2010

Study on immune system activation may help develop new drugs for infections

A new research report in the October 2010 print issue of the Journal of Leukocyte Biology sheds important light on how our immune systems detect invading organisms to be destroyed and removed from our bodies. The information from this research should ultimately help lead to the development of new drugs and treatments that allow health care providers to prevent runaway immune reactions that can have devastating consequences for people.

4 Oct 2010

Scientists identify a new way to cure food allergies

Johns Hopkins scientists have discovered a way to turn off the immune system's allergic reaction to certain food proteins in mice, a discovery that could have implications for the millions of people who suffer severe reactions to foods, such as peanuts and milk.

4 Oct 2010

PDGFR gene rearrangements lead to aggressive form of glioblastoma: Study

4 Oct 2010

Activating rearrangements in receptor genes are more common than previously thought

A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies. The research was led by senior author Eric C. Holland, MD, PhD,--an MSKCC surgeon, researcher and the Director of the Brain Tumor Center--and was published in the October 1 issue of the journal Genes & Development.

1 Oct 2010

Benicar better than Cozaar in reducing blood pressure: Study

New study results show that patients treated with Benicar® (olmesartan medoxomil) 40 mg once daily had significantly greater reductions in blood pressure and higher rates of goal attainment than patients receiving Cozaar® (losartan potassium) 100 mg once daily at week 8, according to findings of a new head-to-head study presented today at the late breaker session at the 23rd Scientific Meeting of the International Society of Hypertension (ISH) in Vancouver, Canada.

1 Oct 2010

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

1 Oct 2010

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.

1 Oct 2010

Breast cancer breakthrough

New research on gene expression provides a breakthrough in breast cancer treatment. Women who have triple-negative breast cancer are a small proportion of breast cancer cases, but it is difficult to treat and might have a more aggressive clinical course than other forms of the disease.

30 Sep 2010

Prix Galien USA committee honors life saving innovations

The Prix Galien USA committee honored innovations that are saving lives last night during the Prix Galien Awards Gala. The Pro Bono Humanum Award, the Prix Galien USA 2010 and the Prix Galien International were presented and related accomplishments celebrated.

30 Sep 2010

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

30 Sep 2010

Warburg Pincus to invest CDN $35 million in Protox

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, and Warburg Pincus, a leading global private equity firm, today jointly announced that they have entered into an Investment Agreement.

30 Sep 2010

Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research

Patients with triple negative breast cancer that also have mutations in the BRCA gene appear to have a lower risk of recurrence, compared to those with the same disease without the deleterious genetic mutation, according to researchers at The University of Texas MD Anderson Cancer Center.

30 Sep 2010

Washington University receives award to develop diagnostic tools for heart, lung diseases using nanotechnology

An $18 million research program headed by Washington University School of Medicine in St. Louis will research therapies and diagnostic tools for heart and lung diseases that use nanotechnology.

30 Sep 2010

Receptor News and Research

Neuraltus achieves last patient out for NP001, NP002 studies

Researchers reveal ways to halt Rett Syndrome

Study finds BRACAnalysis vital for triple negative breast cancer patients

Second pathway to brain’s memory function uncovered

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

Study demonstrates potential of nontoxic envelope proteins as an alternative to pseudotype lentiviral vectors

NIH awards Scripps Research grants to study the mechanisms of protein complex

Study on immune system activation may help develop new drugs for infections

Scientists identify a new way to cure food allergies

PDGFR gene rearrangements lead to aggressive form of glioblastoma: Study

Activating rearrangements in receptor genes are more common than previously thought

Benicar better than Cozaar in reducing blood pressure: Study

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Breast cancer breakthrough

Prix Galien USA committee honors life saving innovations

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Warburg Pincus to invest CDN $35 million in Protox

Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research

Washington University receives award to develop diagnostic tools for heart, lung diseases using nanotechnology

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News